Literature DB >> 22527616

Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.

Federica Guaraldi1, Valentina Corazzini, Gary L Gallia, Silvia Grottoli, Karen Stals, Nadezhda Dalantaeva, Lawrence A Frohman, Márta Korbonits, Roberto Salvatori.   

Abstract

Familial isolated pituitary adenoma (FIPA), defined as the occurrence of at least two cases of pituitary adenoma in a family that does not exhibit features of syndromic diseases, such as Carney complex or Multiple Endocrine Neoplasia type 1 or 4, is a rare autosomal dominant disease with low penetrance. About 20 % of the families with FIPA harbor inactivating mutation in aryl hydrocarbon receptor-interacting protein gene (AIP) associated with loss of heterozygosity of the same genetic locus (11q13) in the tumor. Rarely different types of extra-pituitary tumors have been described in the setting of AIP mutation-positive FIPA. We present the case of a patient who was diagnosed with acromegaly due to the AIP mutation c.241C>T (p.R81X) at the age of 34 years, and treated by transsphenoidal surgery. At the age of 43 years she was diagnosed with a meningioma, and at age 46 had recurrence of the somatotropinoma. Genetic studies demonstrated loss of the normal allele (by sequencing and microsatellite analysis) in DNA from the pituitary adenoma but not from the meningioma, suggesting a selective involvement of AIP mutation in the pathogenesis of the pituitary adenoma, and a casual association with the meningioma. Further investigations are required to define the exact role of AIP in non-pituitary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527616     DOI: 10.1007/s11102-012-0391-y

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  52 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  Effect of treatment with pegvisomant on meningioma growth in vivo.

Authors:  W M Drake; A B Grossman; R K Hutson
Journal:  Eur J Endocrinol       Date:  2005-01       Impact factor: 6.664

3.  Isolated familial somatotropinoma.

Authors:  Beatriz Santana Soares; Lawrence A Frohman
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

4.  [Association of frontal ependymoma and hypophyseal adenoma].

Authors:  G Gori; U Nucci
Journal:  Minerva Neurochir       Date:  1965 Jul-Sep

Review 5.  AIP and its interacting partners.

Authors:  Giampaolo Trivellin; Márta Korbonits
Journal:  J Endocrinol       Date:  2011-03-31       Impact factor: 4.286

Review 6.  Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

Authors:  J J Kopchick; C Parkinson; E C Stevens; P J Trainer
Journal:  Endocr Rev       Date:  2002-10       Impact factor: 19.871

7.  Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationships?

Authors:  E De Menis; G Tulipano; S Villa; D Billeci; C Bonfanti; P Pollara; P Pauletto; A Giustina
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

8.  Familial acromegaly: a specific clinical entity--further evidence from the genetic study of a three-generation family.

Authors:  P Benlian; S Giraud; N Lahlou; M Roger; C Blin; C Holler; G Lenoir; J Sallandre; A Calender; G Turpin
Journal:  Eur J Endocrinol       Date:  1995-10       Impact factor: 6.664

9.  Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations.

Authors:  Marianthi Georgitsi; Anniina Raitila; Auli Karhu; Karoliina Tuppurainen; Markus J Mäkinen; Outi Vierimaa; Ralf Paschke; Wolfgang Saeger; Rob B van der Luijt; Timo Sane; Mercedes Robledo; Ernesto De Menis; Robert J Weil; Anna Wasik; Grzegorz Zielinski; Olga Lucewicz; Jan Lubinski; Virpi Launonen; Pia Vahteristo; Lauri A Aaltonen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-28       Impact factor: 11.205

10.  Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas.

Authors:  Laure Cazabat; Rossella Libè; Karine Perlemoine; Fernande René-Corail; Nelly Burnichon; Anne-Paule Gimenez-Roqueplo; Laurence Dupasquier-Fediaevsky; Xavier Bertagna; Eric Clauser; Philippe Chanson; Jérôme Bertherat; Marie-Laure Raffin-Sanson
Journal:  Eur J Endocrinol       Date:  2007-07       Impact factor: 6.664

View more
  8 in total

1.  A novel C-terminal nonsense mutation, Q315X, of the aryl hydrocarbon receptor-interacting protein gene in a Japanese familial isolated pituitary adenoma family.

Authors:  Takeo Iwata; Shozo Yamada; Junko Ito; Naoko Inoshita; Noriko Mizusawa; Shinji Ono; Katsuhiko Yoshimoto
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

2.  Coexistence of meningioma and other intracranial benign tumors in non-neurofibromatosis type 2 patients: A case report and review of literature.

Authors:  Tian-Hao Hu; Run Wang; Hai-Yun Wang; Yi-Fu Song; Juan-Han Yu; Zi-Xun Wang; Yu-Zhou Duan; Ting Liu; Sheng Han
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

Review 3.  Association of craniopharyngioma and pituitary adenoma.

Authors:  Federica Guaraldi; Nunzia Prencipe; Valentina di Giacomo; Massimo Scanarini; Valentina Gasco; Marina Paola Gardiman; Alessandro M Berton; Ezio Ghigo; Silvia Grottoli
Journal:  Endocrine       Date:  2013-02-02       Impact factor: 3.633

Review 4.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

5.  Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family.

Authors:  Pedro Marques; Sayka Barry; Amy Ronaldson; Arla Ogilvie; Helen L Storr; Peter J Goadsby; Michael Powell; Mary N Dang; Harvinder S Chahal; Jane Evanson; Ajith V Kumar; Joan Grieve; Márta Korbonits
Journal:  Int J Endocrinol       Date:  2018-04-04       Impact factor: 2.803

6.  Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview.

Authors:  Ismene Bilbao Garay; Adrian F Daly; Nerea Egaña Zunzunegi; Albert Beckers
Journal:  J Clin Med       Date:  2020-06-26       Impact factor: 4.241

7.  Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child.

Authors:  Pinaki Dutta; Kavita S Reddy; Ashutosh Rai; Anil K Madugundu; Hitendra S Solanki; Anil Bhansali; Bishan D Radotra; Narendra Kumar; David Collier; Donato Iacovazzo; Prakamya Gupta; Remya Raja; Harsha Gowda; Akhilesh Pandey; Jagtar Singh Devgun; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

8.  New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses.

Authors:  Aysha AlSahlawi; Rasha Aljelaify; Malak Abedalthagafi; Amna Magrashi; Mariam AlSaeed; Amal Almutairi; Fatimah Alqubaishi; Abdulellah Alturkistani; Abdullah AlObaid; Mohamed Abouelhoda; Latifa AlMubarak; Nada AlTassan
Journal:  Oncotarget       Date:  2019-09-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.